PRINCETON, N.J., March 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, is pleased to announce the appointment of Herbert J. Conrad as a member of the Board of Directors and the Nominating and Corporate Governance Committee. Mr. Conrad is currently the Chairman of the Board of Directors of Sapphire Therapeutics, a Director of Savient Pharmaceuticals, Celldex and Symphony Evolution, and serves on the Medical Advisory Board of Henry Schein. From 1960 to 1993, Mr. Conrad served in a variety of marketing and strategic planning roles at Hoffmann LaRoche, and he was the President of the Roche Pharmaceuticals Division and a Member of the Executive Committee and Board of Directors from 1982 through 1993. Mr. Conrad has been involved in a number of business, industry, academic, civic and philanthropic organizations, and he also served in the U.S. Army's Medical Services Corps. Mr. Conrad earned his undergraduate and graduate degrees in Pharmacy from the Brooklyn College of Pharmacy. He also has received a Doctorate in Humane Letters (Honorary) from Long Island University.
"Pharmasset is honored to welcome Herb Conrad to our Board of Directors," stated G. Steven Burrill, CEO of Burrill & Company and Pharmasset's Chairman of the Board of Directors. "Herb has tremendous pharmaceutical industry experience, and we will benefit enormously from his guidance as Pharmasset continues its growth and evolution."
Pharmasset is a pharmaceutical company committed to discovering,
developing and commercializing novel drugs to treat viral infections.
Pharmasset's primary focus is on the developme
|SOURCE Pharmasset, Inc.|
Copyright©2008 PR Newswire.
All rights reserved